Claims for Patent: 10,391,085

Summary for Patent: 10,391,085

Title:	Methods of treating glioblastoma multiforme using ibudilast
Abstract:	Compositions and methods for treating glioblastoma or recurrent glioblastoma and its associated symptoms by administration of ibudilast (3-isobutyryl-2-isopropylpyrazolo[1,5-a]pyridine) or a pharmaceutically acceptable salt thereof.
Inventor(s):	Matsuda; Kazuko (La Jolla, CA), McDonald; Kerrie (Sydney, AU)
Assignee:	MediciNova, Inc. (La Jolla, CA)
Application Number:	15/851,066
Patent Claims:	1. A method of treating a patient diagnosed with glioblastoma or suffering from recurrent glioblastoma comprising administering to the patient a therapeutically effective amount of ibudilast or a pharmaceutically acceptable salt thereof, as part of a combination therapy comprising at least one additional therapy, wherein the at least one additional therapy comprises laquinimod. 2. The method of claim 1 in which the ibudilast or pharmaceutically acceptable salt thereof is administered for at least 3 months. 3. The method of claim 1 in which the ibudilast or pharmaceutically acceptable salt thereof is administered at least once daily. 4. The method of claim 1 in which the ibudilast or pharmaceutically acceptable salt thereof is administered orally. 5. The method of claim 1, wherein the therapeutically effective amount of ibudilast or a pharmaceutically acceptable salt thereof is from 0.1 mg to 720 mg per day. 6. The method of claim 1, wherein the therapeutically effective amount is administered as a single dose or is divided into two, three, or four doses. 7. The method of claim 1, wherein the at least one additional therapy further comprises one or more of radiation therapy, one or more other therapeutic agent, or electric field therapy. 8. The method of claim 7, wherein the one or more other therapeutic agent is temozolomide, carmustine, bevacizumab, procarbazine, hydroxyurea, irinotecan, lomustine, nimotuzumab, sirolimus, mipsagargin, cabozantinib, lomustine, onartuzumab, patupilone (Epothilone B), recombinant oncolytic poliovirus (PVS-RIPO), or any combination of one or more of the foregoing. 9. A method of treating a patient suffering from recurrent glioblastoma comprising administering to the patient a therapeutically effective amount of ibudilast or a pharmaceutically acceptable salt thereof, as part of a combination therapy comprising at least one additional therapy, wherein the at least one additional therapy comprises laquinimod. 10. The method of claim 9 in which the ibudilast or pharmaceutically acceptable salt thereof is administered for at least 3 months. 11. The method of claim 9 in which the ibudilast or pharmaceutically acceptable salt thereof is administered at least once daily. 12. The method of claim 9 in which the ibudilast or pharmaceutically acceptable salt thereof is administered orally. 13. The method of claim 9, wherein the therapeutically effective amount of ibudilast or a pharmaceutically acceptable salt thereof is from 0.1 mg to 720 mg per day. 14. The method of claim 9, wherein the therapeutically effective amount is administered as a single dose or is divided into two, three, or four doses. 15. The method of claim 9, wherein the at least one additional therapy further comprises one or more of radiation therapy, one or more other therapeutic agent, or electric field therapy. 16. The method of claim 15, wherein the one or more other therapeutic agent is temozolomide, carmustine, bevacizumab, procarbazine, hydroxyurea, irinotecan, lomustine, nimotuzumab, sirolimus, mipsagargin, cabozantinib, lomustine, onartuzumab, patupilone (Epothilone B), recombinant oncolytic poliovirus (PVS-RIPO), or any combination of one or more of the foregoing.

Details for Patent 10,391,085

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	AVASTIN	bevacizumab	Injection	125085	02/26/2004		2036-12-22